201 related articles for article (PubMed ID: 26686971)
1. Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma.
Smith JR; Moreno L; Heaton SP; Chesler L; Pearson AD; Garrett MD
Mol Oncol; 2016 Apr; 10(4):538-52. PubMed ID: 26686971
[TBL] [Abstract][Full Text] [Related]
2. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
[TBL] [Abstract][Full Text] [Related]
3. Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo.
Segerström L; Baryawno N; Sveinbjörnsson B; Wickström M; Elfman L; Kogner P; Johnsen JI
Int J Cancer; 2011 Dec; 129(12):2958-65. PubMed ID: 21717457
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo.
Johnsen JI; Segerström L; Orrego A; Elfman L; Henriksson M; Kågedal B; Eksborg S; Sveinbjörnsson B; Kogner P
Oncogene; 2008 May; 27(20):2910-22. PubMed ID: 18026138
[TBL] [Abstract][Full Text] [Related]
5. GD2 ganglioside specific antibody treatment downregulates PI3K/Akt/mTOR signaling network in human neuroblastoma cell lines.
Durbas M; Horwacik I; Boratyn E; Kamycka E; Rokita H
Int J Oncol; 2015 Sep; 47(3):1143-59. PubMed ID: 26134970
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors.
Vaughan L; Clarke PA; Barker K; Chanthery Y; Gustafson CW; Tucker E; Renshaw J; Raynaud F; Li X; Burke R; Jamin Y; Robinson SP; Pearson A; Maira M; Weiss WA; Workman P; Chesler L
Oncotarget; 2016 Sep; 7(36):57525-57544. PubMed ID: 27438153
[TBL] [Abstract][Full Text] [Related]
7. MCPIP1 Exogenous Overexpression Inhibits Pathways Regulating MYCN Oncoprotein Stability in Neuroblastoma.
Boratyn E; Nowak I; Durbas M; Horwacik I; Sawicka A; Rokita H
J Cell Biochem; 2017 Jul; 118(7):1741-1755. PubMed ID: 27935099
[TBL] [Abstract][Full Text] [Related]
8. The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma.
Fulda S
Curr Cancer Drug Targets; 2009 Sep; 9(6):729-37. PubMed ID: 19754357
[TBL] [Abstract][Full Text] [Related]
9. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE
Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590
[TBL] [Abstract][Full Text] [Related]
10. N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma.
Kang J; Rychahou PG; Ishola TA; Mourot JM; Evers BM; Chung DH
Oncogene; 2008 Jun; 27(28):3999-4007. PubMed ID: 18278068
[TBL] [Abstract][Full Text] [Related]
11. A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.
Kushner BH; Cheung NV; Modak S; Becher OJ; Basu EM; Roberts SS; Kramer K; Dunkel IJ
Int J Cancer; 2017 Jan; 140(2):480-484. PubMed ID: 27649927
[TBL] [Abstract][Full Text] [Related]
12. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
[TBL] [Abstract][Full Text] [Related]
13. The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma.
Lampis S; Raieli S; Montemurro L; Bartolucci D; Amadesi C; Bortolotti S; Angelucci S; Scardovi AL; Nieddu G; Cerisoli L; Paganelli F; Valente S; Fischer M; Martelli AM; Pasquinelli G; Pession A; Hrelia P; Tonelli R
J Exp Clin Cancer Res; 2022 Apr; 41(1):160. PubMed ID: 35490242
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive MRI Native T
Zormpas-Petridis K; Poon E; Clarke M; Jerome NP; Boult JKR; Blackledge MD; Carceller F; Koers A; Barone G; Pearson ADJ; Moreno L; Anderson J; Sebire N; McHugh K; Koh DM; Chesler L; Yuan Y; Robinson SP; Jamin Y
Cancer Res; 2020 Aug; 80(16):3424-3435. PubMed ID: 32595135
[TBL] [Abstract][Full Text] [Related]
15. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
[TBL] [Abstract][Full Text] [Related]
16. PI3King the lock: targeting the PI3K/Akt/mTOR pathway as a novel therapeutic strategy in neuroblastoma.
King D; Yeomanson D; Bryant HE
J Pediatr Hematol Oncol; 2015 May; 37(4):245-51. PubMed ID: 25811750
[TBL] [Abstract][Full Text] [Related]
17. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
[TBL] [Abstract][Full Text] [Related]
18. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
19. miR-215-5p is an anticancer gene in multiple myeloma by targeting RUNX1 and deactivating the PI3K/AKT/mTOR pathway.
Liu S; Zhang Y; Huang C; Lin S
J Cell Biochem; 2020 Feb; 121(2):1475-1490. PubMed ID: 31498483
[TBL] [Abstract][Full Text] [Related]
20. PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome.
Mueller S; Phillips J; Onar-Thomas A; Romero E; Zheng S; Wiencke JK; McBride SM; Cowdrey C; Prados MD; Weiss WA; Berger MS; Gupta N; Haas-Kogan DA
Neuro Oncol; 2012 Sep; 14(9):1146-52. PubMed ID: 22753230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
